SCHEMBL7718113

SCHEMBL7718113

CCCCC/C=C\C/C=C\CC(O)/C=C/C=C\CCCC(=O)O

nearest known ligand 0.95

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OXER1 Q8TDS5 3/20 0.95
LTB4R2 Q9NPC1 2/20 0.74
MAPT P10636 2/20 0.74
ALDH1A1 P00352 2/20 0.74
ALOX5 P09917 1/20 0.74
LTB4R Q15722 1/20 0.74
FAAH O00519 3/20 0.69
PPARG P37231 3/20 0.68
KDM4E B2RXH2 1/20 0.68
MEN1 O00255 1/20 0.68
USP2 O75604 1/20 0.68
LMNA P02545 1/20 0.68
TP53 P04637 1/20 0.68
CYP3A4 P08684 1/20 0.68
HSPD1 P10809 1/20 0.68
CYP19A1 P11511 1/20 0.68
FABP4 P15090 1/20 0.68
HPGD P15428 1/20 0.68
ALOX15 P16050 1/20 0.68
CASP1 P29466 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480333 1.00 OXER1 (0.95) OXER1LTB4R2MAPTALDH1A1ALOX5
SCHEMBL29926444 1.00 OXER1 (0.95) OXER1LTB4R2MAPTALDH1A1ALOX5
SCHEMBL8728913 1.00 OXER1 (0.95) OXER1LTB4R2MAPTALDH1A1ALOX5
SCHEMBL1479341 1.00 OXER1 (0.95) OXER1LTB4R2MAPTALDH1A1ALOX5
SCHEMBL7718095 1.00 OXER1 (0.95) OXER1LTB4R2MAPTALDH1A1ALOX5
SCHEMBL29926968 1.00 OXER1 (0.95) OXER1LTB4R2MAPTALDH1A1ALOX5
SCHEMBL29926582 1.00 OXER1 (0.95) OXER1LTB4R2MAPTALDH1A1ALOX5
SCHEMBL1480331 1.00 OXER1 (0.95) OXER1LTB4R2MAPTALDH1A1ALOX5
SCHEMBL1479340 1.00 OXER1 (0.95) OXER1LTB4R2MAPTALDH1A1ALOX5
SCHEMBL16670813 0.97 OXER1 (1.00) OXER1LTB4R2MAPTALDH1A1ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4704797-A1 OXYLIPINS IN THE TREATMENT OF SEBORRHEA Pierre Fabre Dermo-Cosmétique (FR) 2026-03-11 EP claimed
EP-4687496-A1 COMPOSITION COMPRISING OXYLIPINS PRESENT IN HUMAN MILK DERIVED SMALL EXTRACELLULAR VESICLES AND ITS USE IN THE PREVENTION AND TREATMENT OF INTESTINAL DISEASES Fundación Para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana (ES) 2026-02-11 EP claimed
US-20250216407-A1 LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS INIPHARM, INC. 2025-07-03 US claimed
CN-119069037-B Detection method of heart failure detection biomarker based on oxidized lipid derivatization and machine learning model 中国中医科学院医学实验中心 2025-02-14 CN claimed
EP-4468884-A1 LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT Amarin Pharmaceuticals Ireland Limited (IE) 2024-12-04 EP claimed
CN-119069037-A Detection method of heart failure detection biomarker based on oxidized lipid derivatization and machine learning model 中国中医科学院医学实验中心 2024-12-03 CN claimed
WO-2024227714-A1 OXYLIPINS IN THE TREATMENT OF SEBORRHEA PIERRE FABRE DERMO-COSMETIQUE (FR) 2024-11-07 WO claimed
WO-2024200855-A1 COMPOSITION COMPRISING OXYLIPINS PRESENT IN HUMAN MILK DERIVED SMALL EXTRACELLULAR VESICLES AND ITS USE IN THE PREVENTION AND TREATMENT OF INTESTINAL DISEASES FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO Y POLITECNICO LA FE DE LA COMUNIDAD VALENCIANA (ES) 2024-10-03 WO claimed
EP-4437858-A1 COMPOSITION COMPRISING OXYLIPINS PRESENT IN HUMAN MILK DERIVED SMALL EXTRACELLULAR VESICLES AND ITS USE IN THE PREVENTION AND TREATMENT OF INTESTINAL DISEASES Fundación Para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana (ES) 2024-10-02 EP claimed
CN-118714935-A Lymphoreleased fatty acid compositions and their use for lymphatic incorporation and systemic disease treatment 阿马里纳药物爱尔兰有限公司 2024-09-27 CN claimed
EP-4329742-A1 COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT Amarin Pharmaceuticals Ireland Limited (IE) 2024-03-06 EP claimed
WO-2023192314-A1 LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS INIPHARM, INC. (US) 2023-10-05 WO claimed
US-20230284643-A1 MILK PRODUCT COMPOSITIONS BIOMILQ INC (US) 2023-09-14 US claimed
WO-2023146984-A1 LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) 2023-08-03 WO claimed
WO-2023083380-A1 METHOD FOR PREDICTING PROGNOSIS OF PATIENT WITH HEART FAILURE WITH ARACHIDONIC ACID METABOLOME DATA IN SERUM 北京市心肺血管疾病研究所 2023-05-19 WO claimed
EP-4157990-A1 MILK PRODUCT COMPOSITIONS Biomilq, Inc. (US) 2023-04-05 EP claimed
US-20230043035-A1 AGAROPHYTON CHILENSIS EXTRACT, RICH IN FREE FATTY ACIDS, AS A NUTRACEUTICAL OR NUTRITIONAL SUPPLEMENT, SUITABLE FOR MODULATING PPAR# ACTIVITY UNIVERSIDAD ANDRES BELLO (CL) 2023-02-09 US claimed
CN-115698252-A Dairy product composition 生物乳业公司 2023-02-03 CN claimed
WO-2022232633-A1 COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) 2022-11-03 WO claimed
CN-114034851-A Method for predicting prognosis of heart failure patient by using arachidonic acid metabolome data in serum 北京市心肺血管疾病研究所 2022-02-11 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230043035-A1 AGAROPHYTON CHILENSIS EXTRACT, RICH IN FREE FATTY ACIDS, AS A NUTRACEUTICAL OR NUTRITIONAL SUPPLEMENT, SUITABLE FOR MODULATING PPAR# ACTIVITY PPARG, FFAR1, PPARA OXER1 103/4885LTB4R2 1024/4885MAPT 2540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.